Clonality and Evolutionary History of Rhabdomyosarcoma

English version České info

To decipher the dynamic mutational process and identify the causative genomic events in rhabdomyosarcoma (RMS), we developed a systematic method that incorporates multiple types of genomic information to estimate normal cell contamination, tumor clonality, and a timeline of somatic events that occurred prior to the tumor presentation. Our results demonstrate two distinct evolutionary paths resulting in PAX-fusion-negative-rhabdomyosarcoma (PFN-RMS) and PAX-fusion-positive-rhabdomyosarcoma (PFP-RMS): (1) In PFN-RMS, genomic loss of heterozygosity on chromosome 11p15.5 and non-synonymous mutations in RAS pathway and cell cycle genes (FGFR4, KRAS, NRAS, HRAS and CCDN1), as well as several genes not previously known to be drivers of RMS, including PKN1, CUL2, and TTK, occurs early in the evolutionary history of tumor; (2) In contrast, the PAX gene fusion event in PFP-RMS tumors is an early detectable event which consistently occurs prior to a whole genome duplication event. These findings provide new insights into the biology and molecular events that initiate RMS tumorigenesis and may help identify actionable drivers for targeted therapies.

Vyšlo v časopise: Clonality and Evolutionary History of Rhabdomyosarcoma. PLoS Genet 11(3): e32767. doi:10.1371/journal.pgen.1005075
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1005075

Souhrn

Zdroje

1. Yates LR, Campbell PJ (2012) Evolution of the cancer genome. Nat Rev Genet 13: 795–806. doi: 10.1038/nrg3317 23044827

2. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, et al. (2012) The life history of 21 breast cancers. Cell 149: 994–1007. doi: 10.1016/j.cell.2012.04.023 22608083

3. Tomasetti C, Vogelstein B, Parmigiani G (2013) Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc Natl Acad Sci U S A 110: 1999–2004. doi: 10.1073/pnas.1221068110 23345422

4. Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 458: 719–724. doi: 10.1038/nature07943 19360079

5. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, et al. (2011) Initial genome sequencing and analysis of multiple myeloma. Nature 471: 467–472. doi: 10.1038/nature09837 21430775

6. Ding L, Ellis MJ, Li S, Larson DE, Chen K, et al. (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464: 999–1005. doi: 10.1038/nature08989 20393555

7. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, et al. (2010) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363: 2424–2433. doi: 10.1056/NEJMoa1005143 21067377

8. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, et al. (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475: 101–105. doi: 10.1038/nature10113 21642962

9. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, et al. (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481: 506–510. doi: 10.1038/nature10738 22237025

10. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114–1117. doi: 10.1038/nature09515 20981102

11. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, et al. (2013) Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152: 714–726. doi: 10.1016/j.cell.2013.01.019 23415222

12. Shanafelt TD, Hanson C, Dewald GW, Witzig TE, LaPlant B, et al. (2008) Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. J Clin Oncol 26: e5–6. doi: 10.1200/JCO.2008.16.7874 18467710

13. Shah SP, Roth A, Goya R, Oloumi A, Ha G, et al. (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486: 395–399. doi: 10.1038/nature10933 22495314

14. Durinck S, Ho C, Wang NJ, Liao W, Jakkula LR, et al. (2011) Temporal Dissection of Tumorigenesis in Primary Cancers. Cancer Discovery 1: 137–143. doi: 10.1158/2159-8290.CD-11-0028 21984974

15. Ognjanovic S, Linabery AM, Charbonneau B, Ross JA (2009) Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975–2005. Cancer 115: 4218–4226. doi: 10.1002/cncr.24465 19536876

16. Malempati S, Hawkins DS (2012) Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer 59: 5–10. doi: 10.1002/pbc.24118 22378628

17. Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, et al. (2003) Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21: 78–84. 12506174

18. Linardic CM (2008) PAX3-FOXO1 fusion gene in rhabdomyosarcoma. Cancer Lett 270: 10–18. doi: 10.1016/j.canlet.2008.03.035 18457914

19. Scrable H, Cavenee W, Ghavimi F, Lovell M, Morgan K, et al. (1989) A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci U S A 86: 7480–7484. 2798419

20. Stratton MR, Fisher C, Gusterson BA, Cooper CS (1989) Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Research 49: 6324–6327. 2680062

21. Shukla N, Ameur N, Yilmaz I, Nafa K, Lau CY, et al. (2012) Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res 18: 748–757. doi: 10.1158/1078-0432.CCR-11-2056 22142829

22. Taylor JGt, Cheuk AT, Tsang PS, Chung JY, Song YK, et al. (2009) Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 119: 3395–3407. doi: 10.1172/JCI39703 19809159

23. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, et al. (2014) Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov 4: 216–231. doi: 10.1158/2159-8290.CD-13-0639 24436047

24. Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, et al. (2013) Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 24: 710–724. doi: 10.1016/j.ccr.2013.11.002 24332040

25. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, et al. (2013) Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31: 213–219. doi: 10.1038/nbt.2514 23396013

26. Stamatoyannopoulos JA, Adzhubei I, Thurman RE, Kryukov GV, Mirkin SM, et al. (2009) Human mutation rate associated with DNA replication timing. Nature Genetics 41: 393–395. doi: 10.1038/ng.363 19287383

27. Chen CL, Rappailles A, Duquenne L, Huvet M, Guilbaud G, et al. (2010) Impact of replication timing on non-CpG and CpG substitution rates in mammalian genomes. Genome Research 20: 447–457. doi: 10.1101/gr.098947.109 20103589

28. Xia SJ, Pressey JG, Barr FG (2002) Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 1: 97–104. 12170781

29. Barr FG, Nauta LE, Davis RJ, Schafer BW, Nycum LM, et al. (1996) In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. Human Molecular Genetics 5: 15–21. 8789435

30. Mukai H (2003) The structure and function of PKN, a protein kinase having a catalytic domain homologous to that of PKC. Journal of Biochemistry 133: 17–27. 12761194

31. James RG, Bosch KA, Kulikauskas RM, Yang PTT, Robin NC, et al. (2013) Protein Kinase PKN1 Represses Wnt/beta-Catenin Signaling in Human Melanoma Cells. Journal of Biological Chemistry 288: 34658–34670. doi: 10.1074/jbc.M113.500314 24114839

32. Marinissen MT, Chiariello M, Gutkind JS (2001) Regulation of gene expression by the small GTPase Rho through the ERK6 (p38 gamma) MAP kinase pathway. Genes & Development 15: 535–553.

33. Kohsaka S, Shukla N, Ameur N, Ito T, Ng CKY, et al. (2014) A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nature Genetics 46: 595–600. doi: 10.1038/ng.2969 24793135

34. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, et al. (2003) High frequency of BRAF mutations in nevi. Nature Genetics 33: 19–20. 12447372

35. Chan TL, Zhao W, Leung SY, Yuen ST, Project CG (2003) BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Research 63: 4878–4881. 12941809

36. Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, et al. (2008) Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322: 1377–1380. doi: 10.1126/science.1164266 19039135

37. Henry I, Bonaitipellie C, Chehensse V, Beldjord C, Schwartz C, et al. (1991) Uniparental Paternal Disomy in a Genetic Cancer-Predisposing Syndrome. Nature 351: 665–667. 1675767

38. KOUFOS A, HANSEN MF, LAMPKIN BC, WORKMAN ML, COPELAND NG, et al. (1984) Loss of alleles at loci on human chromosome 11 during genesis of Wilms' tumour. Nature 309: 170–172. 6325936

39. Gripp KW (2005) Tumor predisposition in Costello syndrome. American Journal of Medical Genetics Part C-Seminars in Medical Genetics 137C: 72–77. 16010679

40. Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS (2011) Cancer in Noonan, Costello, Cardiofaciocutaneous and LEOPARD Syndromes. American Journal of Medical Genetics Part C-Seminars in Medical Genetics 157C: 83–89. doi: 10.1002/ajmg.c.30300 21500339

41. Sung L, Anderson JR, Arndt C, Raney B, Meyer WH, et al. (2004) Neurofibromatosis in children with rhabdomyosarcoma: A report from the intergroup Rhabdomyosarcoma Study IV. Journal of Pediatrics 144: 666–668. 15127010

42. DeBaun MR, Tucker MA (1998) Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. Journal of Pediatrics 132: 398–400. 9544889

43. James RG, Bosch KA, Kulikauskas RM, Yang PT, Robin NC, et al. (2013) Protein kinase PKN1 represses Wnt/beta-catenin signaling in human melanoma cells. J Biol Chem 288: 34658–34670. doi: 10.1074/jbc.M113.500314 24114839

44. Dong LQ, Landa LR, Wick MJ, Zhu L, Mukai H, et al. (2000) Phosphorylation of protein kinase N by phosphoinositide-dependent protein kinase-1 mediates insulin signals to the actin cytoskeleton. Proc Natl Acad Sci U S A 97: 5089–5094. 10792047

45. Potthoff MJ, Olson EN (2007) MEF2: a central regulator of diverse developmental programs. Development 134: 4131–4140. 17959722

46. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, et al. (2011) The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells. Cell 147: 759–772. doi: 10.1016/j.cell.2011.09.048 22078877

47. Tremblay AM, Missiaglia E, Galli GG, Hettmer S, Urcia R, et al. (2014) The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation. Cancer Cell 26: 273–287. doi: 10.1016/j.ccr.2014.05.029 25087979

48. Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, et al. (2014) KRAS and YAP1 Converge to Regulate EMT and Tumor Survival. Cell 158: 171–184. doi: 10.1016/j.cell.2014.06.004 24954536

49. Kapoor A, Yao WT, Ying HQ, Hua SJ, Liewen A, et al. (2014) Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer. Cell 158: 185–197. doi: 10.1016/j.cell.2014.06.003 24954535

50. De Zen L, Sommaggio A, d'Amore ES, Masiero L, di Montezemolo LC, et al. (1997) Clinical relevance of DNA ploidy and proliferative activity in childhood rhabdomyosarcoma: a retrospective analysis of patients enrolled onto the Italian Cooperative Rhabdomyosarcoma Study RMS88. Journal of Clinical Oncology 15: 1198–1205. 9060564

51. Whang-Peng J, Knutsen T, Theil K, Horowitz ME, Triche T (1992) Cytogenetic studies in subgroups of rhabdomyosarcoma. Genes Chromosomes Cancer 5: 299–310. 1283318

52. Ganem NJ, Storchova Z, Pellman D (2007) Tetraploidy, aneuploidy and cancer. Current Opinion in Genetics & Development 17: 157–162.

53. Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, et al. (1996) 17P (p53) allelic losses, 4N (G(2)/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Gastroenterology 110: A515–A515.

54. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, et al. (2005) Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 437: 1043–1047. 16222300

55. Nishijo K, Chen QR, Zhang L, McCleish AT, Rodriguez A, et al. (2009) Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma. Cancer Research 69: 2902–2911. doi: 10.1158/0008-5472.CAN-08-3723 19339268

56. Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, et al. (2008) Defining the Cooperative Genetic Changes That Temporally Drive Alveolar RhabdomyosarcomaU. Cancer Research 68: 9583–9588. doi: 10.1158/0008-5472.CAN-07-6178 19047133

57. Pappo AS, Anderson JR, Crist WM, Wharam MD, Breitfeld PP, et al. (1999) Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the intergroup rhabdomyosarcoma study group. Journal of Clinical Oncology 17: 3487–3493. 10550146

58. Trapnell C, Pachter L, Salzberg SL (2009) TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25: 1105–1111. doi: 10.1093/bioinformatics/btp120 19289445

59. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, et al. (2010) Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28: 511–515. doi: 10.1038/nbt.1621 20436464

60. Lam HY, Clark MJ, Chen R, Natsoulis G, O'Huallachain M, et al. (2012) Performance comparison of whole-genome sequencing platforms. Nat Biotechnol 30: 78–82. doi: 10.1038/nbt.2065 22178993

61. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, et al. (2012) Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483: 589–593. doi: 10.1038/nature10910 22367537

62. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, et al. (2011) Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nature Genetics 43: 442–446. doi: 10.1038/ng.810 21499247

63. Turajlic S, Furney SJ, Lambros MB, Mitsopoulos C, Kozarewa I, et al. (2012) Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res 22: 196–207. doi: 10.1101/gr.125591.111 22183965